Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been assigned a consensus recommendation of “Buy” from the nineteen analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, sixteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $295.3889.
Several research firms have commented on ASND. Wells Fargo & Company decreased their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus set a $332.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. Wolfe Research restated an “outperform” rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a research report on Monday, March 16th. They issued a “buy” rating and a $290.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd.
View Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. Analysts anticipate that Ascendis Pharma A/S will post 4.55 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Jean Jacques Bienaime bought 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director directly owned 400 shares in the company, valued at approximately $95,120. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The SEC filing for this sale provides additional information. Company insiders own 40.00% of the company’s stock.
Institutional Trading of Ascendis Pharma A/S
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 2.6% during the third quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock worth $1,015,919,000 after buying an additional 130,000 shares during the last quarter. Capital International Investors raised its stake in Ascendis Pharma A/S by 0.4% during the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after purchasing an additional 13,685 shares during the last quarter. Wellington Management Group LLP raised its stake in Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after purchasing an additional 880,836 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares during the period. Finally, Principal Financial Group Inc. grew its position in Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after purchasing an additional 232,730 shares during the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
